Evolution of Resistance to Irinotecan in Cancer Cells Involves Generation of Topoisomerase-Guided Mutations in Non-Coding Genome That Reduce the Chances of DNA Breaks

Keyphrases

• Adaptation 33%
• Cancer Cells 100%
• Cleavage Site 33%
• Cytotoxicity 33%
• DNA Breaks 100%
• DNA Double-strand Breaks 33%
• Drug Exposure 66%
• Drug Resistance 33%
• Drug Resistance Mechanisms 33%
• Drug Treatment 33%
• Expression Level 33%
• Guided mutation 100%
• Homologous Recombination Repair 33%
• In Cancer 100%
• Irinotecan 100%
• Large Targets 33%
• Multiple Drugs 33%
• Non-coding Genome 100%
• Non-coding Region 33%
• Normal Sequences 33%
• Recurrent mutation 33%
• Reference Genome 33%
• Resistance Development 33%
• Resistance Evolution 100%
• Resistance Mechanisms 33%
• Resistance mutations 66%
• Resistance to Chemotherapy 33%
• Resistant mutants 33%
• Specificity Protein 1 33%
• Target Size 33%
• TOP1 Inhibitor 33%
• Topoisomerase 100%
• Treatment Failure 33%

Biochemistry, Genetics and Molecular Biology

• Cancer Cell 100%
• Coding Region 50%
• Cytotoxicity 50%
• DNA Topoisomerase 100%
• Drug Exposure 100%
• Drug Resistance 100%
• Homologous Recombination 50%
• Recombination Repair 50%
• Topoisomerase 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 33%
• Cytotoxicity 33%
• DNA Topoisomerase 100%
• Double Stranded DNA 33%
• Drug Resistance 66%
• Irinotecan 100%
• Malignant Neoplasm 100%
• Pharmacotherapy 33%
• Protein 33%